The Monash University Institute of Pharmaceutical Sciences (MIPS) has announced positive results from a Phase 1 study of inhaled oxytocin in healthy volunteers. The study was conducted by GSK, which is partnered with Monash University to develop inhaled oxytocin for the treatment of postpartum hemorrhage.
According to MIPS, the PK data presented at the Royal College of Obstetricians and Gynaecologists World Congress show no significant differences between oxytocin delivered by inhalation or by injection.
MIPS Project Leader Michelle McIntosh commented, “These results show that oxytocin can be delivered similarly via inhalation or injection and therefore we are less likely to be required to conduct the extensive and costly trials needed for an entirely new drug. Instead, we should be able to move forward with trials on a much smaller scale, featuring patients numbering in the hundreds rather than tens of thousands, potentially making the medicine available much sooner.”
Read the Monash University press release.
